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Introduction: The combination of mitral valve replacement (MVR) with coronary artery bypass grafting
(CABG) is generally thought to have a greater early and late mortality than either procedure alone. The
aim of this study is to review single center experience for the concomitant MVR and CABG.
Patients and methods: This is a single center, retrospective, single cohort study, composes of consecutive
cases. It included all the cases of combined operation of MVR and CABG. The patients were followed up
for a median duration of two years (six months to four years). The data were collected from hospital
records and registers of hospital statistics. The followings were obtained; socio-demographic data, in-
formation regarding clinical courses, intraoperative findings, and post-operative follow up data.
Result: The study included 72 cases, the mean age was 56 years, 38 of them (53%) were males and 34
(47%) were female. The most common comorbidity was hypertension which was found in 24 patients
(33%). The mean preoperative ejection fraction was 59%. Twenty-two patients (30.6%) had single graft, 21
patients (29.2%) underwent 3-vessel grafting, 16 patients (22.2%) had 2-vessel grafting, and 13 cases
(18.1%) underwent 4-vessel grafting. The CPB duration ranged from 108 to 280 min with a mean of
182 min and cross-clamp time ranged from 80 to 186 min with a mean of 122 min. The most common
complication was plural effusion which occurred in 8 cases (11.1%) and managed by aspiration. Overall
mortality was 8.3% (4 patients).
Conclusion: CABG and chordal-sparing and posterior leaflet replacement has favorable outcome, as well
as minimizes the need of redo surgery as in repair.one of the best options for CAD and sever MR.
© 2021 The Author(s). Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mitral valve disorder is one of the most common valvular heart
diseases in the developed countries reaching about 2% of generalartment 50, Sulaimani, 0064,
. Kakamad).
vier Ltd on behalf of Surgical Assopopulation [1,2]. Patients who have both mitral valve dysfunction
and atherosclerotic coronary artery disease (CAD) form a hetero-
geneous group in terms of origin of the valvular disease, extent of
coronary atherosclerosis, left ventricular dyfunction, and hemo-
dynamic status at operation [3]. Chronic ischemic mitral regurgi-
tation (IMR) is a frequent and important complication after
myocardial infarction. Its pathophysiologic mechanisms account
for remodeling of segmental/global left ventricle (LV) inducing
papillary muscle displacement and leaflet tethering [4].ciates Ltd. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Comorbidities of the participants.
Comorbidities Number (%)
Hypertension 24 (33)
Diabetes mellitus 20 (27)
Dyslipidemia 16 (25.8)
Atrial fibrillation 8 (11)
Chronic obstructive airway disease 4 (5.5)
Stroke 2 (2.7)
Percutaneous coronary intervention 2 (2.7)
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replacement for non-ischemic mitral valve disease need coronary
artery bypass grafting (CABG) [5,6]. The combination of mitral valve
replacement (MVR) with CABG is generally thought to have a
greater early and late mortality than either procedure alone.
Although CAD is often associated with mitral valve disease, but it
may not be the cause of the valve dysfunction [7]. Current guide-
lines recommend mitral valve surgery for severe IMR, but do not
demonstrate a specific type of procedure like combination opera-
tion [8,9]. The aim of this study is to review single center experi-
ence for the concomitant MVR and CABG. The study has been
written in line with process guidelines [10].
2. Patients and methods
2.1. Design and setting
This is a single center, retrospective, single cohort study, com-
poses of consecutive cases during four year period (2016e2020). It
included all the cases of combined operation of MVR and CABG.
Those patients with double valvular intervention were excluded
from the study. Follow-up of patients was performed through
clinical visits and telephone interviews with patients and/or their
family. The patients were followed up for a median duration of two
years (six months to four years).
2.2. Registration
The research was registered in Chinese Clinical Trial Registry.




All patients underwent transthoracic echocardiography (TTE)
and preoperative coronary angiography. Carotid Doppler study was
requested for those patients with previous stroke and/or peripheral
vascular disease (PVD).
2.4. Operative intervention
Standard cardiac surgery monitoring was used. The operation
was performed through a complete median sternotomy. Before the
institution of cardiopulmonary bypass (CPB) the grafts were har-
vested. The left internal mammary artery (LIMA) was harvested in
the pedicle fashion. The saphenous vein was harvested in the
standard fashion. After heparin administration CPB was instituted,
aortic cross clamping, Normohermia used for patients with
borderline renal function, and mild hypothermia for the rest. Del-
nido, blood cardioplegia was used in all cases, induction was
commenced by antegade root, and maintenance by retrograde one.
Venting the left ventricle was established through superior pul-
monary vein. Distal anastomoses were done first, followedy left
atriotomy. The anterior leaflets were removed wile posterior one
preserved. All of the patients underwent prosthetic mitral valve
replacement. No repair was attempted because all of the cases were
young, there was a limited experience in repair and no consensus
guidelines preferring repair over replacement. Separated suture
technique was performed to implant the mitral prosthesis. The
heart was de-aired and the aortic clamp was removed. The prox-
imal anastomoses were done lastly. Mediastinal and pleural drains
were placed before chest closure. Post operatively, all patients were
kept on oral anticoagulant and antiplatelet.2
2.5. Data collection
The data were collected from hospital records and registers of
hospital statistics. The followings were obtained; socio-
demographic data, information regarding clinical courses, intra-
operative findings, and post-operative follow up data.
2.6. Data analysis
The information was collected and registered into an excel file,
after coding of the data, a Statistical Package for Social Sciences
(SPSS) software was used to analyze the data. Frequency, percent-
age, mean and range (descriptive statistics) were calculated to
present the data.
3. Result
The study included 72 cases, themean agewas 56 years (ranging
from 42 years to 78 years), 38 of them (53%) were males and 34
(47%) were female. The most common comorbidity was hyperten-
sion which was found in 24 patients (33%) (Table 1). The mean
preoperative ejection fraction was 59% (ranging from 40% to 62%).
Twenty-two patients (30.6%) had single graft, 21 patients (29.2%)
underwent 3-vessel grafting, 16 patients (22.2%) had 2-vessel
grafting, and 13 cases (18.1%) underwent 4-vessel grafting. The
CPB duration ranged from 108 to 280 min with a mean of 182 min
and cross-clamp time ranged from 80 to 186 min with a mean of
122 min. The average duration of admission to the intensive care
unit was 51 h ranging from 48 h to 72 h. The patients stayed at
hospital a mean of 7 days (ranging from 5 to 10 days). The most
common complication was plural effusion which occurred in 8
cases (11.1%) and managed by aspiration (Table 2).
Overall mortality was 8.3% (4 patients), the causes were as the
followings; failure of weaning from bypass in one case (1.4%), CVA
in one case (1.4%), multi-organ failure in one case (1.4%) and cardiac
tamponade in one case (1.4%) who was presented two weeks after
operation.
4. Discussion
Despite the prevalence of IMR in patients referred for surgical
revascularization and its association with poorer clinical outcomes,
the optimal management of moderate to-severe IMR remains un-
clear [11].
Acker et al. Found that chordal-sparingmitral valve replacement
has no significant difference with mitral valve repair in patients
with severe ischemic mitral disease. This conclusion was based on
the absence of a significant difference in left ventricular reverse
remodeling and in the rate of major adverse cardiac or cerebro-
vascular events at 12 months. Mitral valve replacement provides a
considerably more durable correction of mitral regurgitation,
which may have an important effect on long-term outcomes [12]. A




Pleural effusion 8 (11.1)
Arrhythmia 8 (11.1)
Heart block 4 (5.5)
Renal impairment 4 (5.5)
Respiratory complication 3 (4.2)
Pericardial effusion 2 (2.7)
Deep sternal wound infection 2 (2.7)
Re exploration 2 (2.7)
Stroke 2 (2.7)
Gastrointestinal bleeding 2 (2.7)
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both mitral valve procedures showed no significant difference in
left ventricular function at follow-up [13]. However, replacement
had greater thromboembolic and ischemic stroke rates than repair
despite anticoagulant therapy [14].
In a meta-analysis by Wang et al. which covered 11 studies,
including those patients undergoing repair or replacement elec-
tively with CABG surgery, no differences were found regarding
peri-operative mortality and long-term survival. However mitral
valve replacement was associated with lower incidence of mitral
regurgitation in patients with IMR during CABG [15].
In this study all of the cases underwent MVR.
CPB and aortic cross-clamp duration was found to be signifi-
cantly higher in patients undergoing CABG and MV surgery. This is
an intuitive finding given the increased complexity of a combined
procedure. Longer CPB and aortic cross-clamp duration has been
linked with a number of complications, including micro emboli,
increased transfusion requirements, coagulation defects, and
immunosuppression [14]. The combined operation mandate a
prolonged operation in term of both cross clamp time and CPB
duration. Mantovani and associates reported an average of 173 min
of CPB duration and 131 min of cross clamp time while Ljubacev
and colleagues reported 152 min of CPB and 99 min of cross clamp
time [16]. In the current study, the CPB was 182 min and cross
clamp time was 122 min.
Valve replacement in patients who require CABG for associated
coronary artery disease presents a unique problem in achieving and
maintaining adequate myocardial protection. Earlier studies of
simultaneous valve replacement and CABG showed a higher risk for
the combined procedure [17]. The impact of etiology of associated
mitral disease and a valve procedure on operative and long term
outcomes after coronary bypass grafting surgery is yet to be clearly
defined. Several studies have shown that severe CAD, acute
myocardial infarction, low ejection fraction, ischemic mitral
regurgitation, advanced heart failure symptoms, failure to use in-
ternal mammary artery, valve replacement surgery and emergency
operations are important predictors of operative mortality. Other
investigators showed that among the preoperative criteria, only
congestive heart failure (CHF) was a risk factor for in-hospital
mortality after concurrent CABG with MVR operation, whereas
age, history of other major predisposing factors for CAD, and NYHA
score did not influence on in-hospital mortality [18]. The Society of
Thoracic Surgeons declared that mitral valve repair þ CABG group
had approximately 5% (4.8% in-hospital mortality and 5.3% opera-
tive mortality) nationwide mortality rates in contrast with 8% (7.8%
in-hospital mortality and 8.5% operative mortality) for
MVR þ CABG group [19]. In this study, the mortality rate was 8.3%.
There are important limitations for this study that cannot be
neglected; small sample size, study design (no comparison group),
single center, and lack of experience in valve repair.3
5. Conclusion
CABG and chordal-sparing and posterior leaflet replacement has
favorable outcome, as well asminimizes the need of redo surgery as
in repair.one of the best options for CAD and sever MR.
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